SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE2.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro and in vivo laboratory study without human clinical data.
PubMed 33300001 · doi:10.1101/2020.12.04.409144
What was done
The authors evaluated the direct effects of the SARS-CoV-2 Spike (S) protein on vascular endothelial cells using in vitro cell culture and in vivo models. They evaluated cellular markers of endothelial function, including mitochondrial function, ACE2 expression levels, endothelial nitric oxide synthase (eNOS) activity, glycolysis, and upstream regulatory signaling pathways involving AMPK and MDM2.
What was found
The abstract reports qualitative directional changes without specific numerical values, effect sizes, or statistical metrics: - SARS-CoV-2 S protein alone damaged vascular endothelial cells both in vitro and in vivo. - S protein exposure led to impaired mitochondrial function, reduced ACE2 expression, decreased eNOS activity, and elevated glycolysis. - Mechanistically, S protein downregulated AMPK and upregulated MDM2, resulting in ACE2 destabilization.
Why it matters
This study outlines a cellular mechanism by which SARS-CoV-2 spike protein may directly trigger vascular endotheliitis and endothelial dysfunction independently of active viral replication, clarifying cardiovascular complications observed in COVID-19.
Limits
This is basic preclinical bench research (in vitro and animal models); clinical applicability to human physiology remains unverified here. The abstract does not disclose the specific animal species, exposure concentrations or delivery methods of the S protein, sample sizes, or quantitative data and confidence intervals. The record reflects a preprint repository publication.
Cited by
- supports Intratracheal injection of a pseudovirus expressing the SARS-CoV-2 spike protein into hamsters caused severe lung damage and entered circulation to produce vascular damage.